Review

Insulin resistance and hyperglycaemia in cardiovascular disease development

  • Nature Reviews Endocrinology 10, 293302 (2014)
  • doi:10.1038/nrendo.2014.29
  • Download Citation
Published online:

Abstract

The prevalence of diabetes mellitus will likely increase globally from 371 million individuals in 2013 to 552 million individuals in 2030. This epidemic is mainly attributable to type 2 diabetes mellitus (T2DM), which represents about 90–95% of all cases. Cardiovascular disease is the leading cause of mortality among individuals with diabetes mellitus, and >50% of patients will die from a cardiovascular event—especially coronary artery disease, but also stroke and peripheral vascular disease. Classic risk factors such as elevated levels of LDL cholesterol and blood pressure, as well as smoking, are risk factors for adverse cardiovascular events in patients with type 1 diabetes mellitus (T1DM) and T2DM to a similar degree as they are in healthy individuals. Patients with T1DM develop insulin resistance in the months after diabetes mellitus diagnosis, and patients with T2DM typically develop insulin resistance before hyperglycaemia occurs. Insulin resistance and hyperglycaemia, in turn, further increase the risk of adverse cardiovascular events. This Review discusses the mechanisms by which T1DM and T2DM can lead to cardiovascular disease and how these relate to the risk factors for coronary artery disease.

  • Subscribe to Nature Reviews Endocrinology for full access:

    $199

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    , & Type 2 diabetes mellitus—an autoimmune disease? Nat. Rev. Endocrinol. 9, 750–755 (2013).

  2. 2.

    International Diabetes Federation. IDF Diabetes Atlas, 6th edn (International Diabetes Federation, 2013).

  3. 3.

    et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095–2128 (2012).

  4. 4.

    & Global burden of disease—where does diabetes mellitus fit in? Nat. Rev. Endocrinol. 9, 258–260 (2013).

  5. 5.

    , , & Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16, 434–444 (1993).

  6. 6.

    et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am. J. Cardiol. 59, 750–755 (1987).

  7. 7.

    & Type 1 diabetes, hyperglycaemia, and the heart. Lancet 371, 1790–1799 (2008).

  8. 8.

    et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 26, 1374–1379 (2003).

  9. 9.

    et al. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 55, 1463–1469 (2006).

  10. 10.

    et al. Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. Diabetes Care 27, 530–537 (2004).

  11. 11.

    et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 46, 760–765 (2003).

  12. 12.

    et al. Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. Diabetes 52, 2833–2839 (2003).

  13. 13.

    et al. Risks of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med. 9, e1001321 (2012).

  14. 14.

    , , , & Cause-specific mortality in diabetes: recent changes in trend mortality. Eur. J. Prev Cardiol. 19, 374–381 (2012).

  15. 15.

    & Type 2 diabetes in East Asians: similarities and differences with populations in Europa and the United States. Ann. NY Acad. Sci. 1281, 64–91 (2013).

  16. 16.

    , , , & Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339, 229–234 (1998).

  17. 17.

    , , , & Type 2 diabetes as a “coronary heart disease equivalent”: an 18-year prospective population-based study in Finnish subjects. Diabetes Care 28, 2901–2907 (2005).

  18. 18.

    et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 117, 1945–1954 (2008).

  19. 19.

    , , & Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet. Med. 26, 142–148 (2009).

  20. 20.

    & Update on type 2 diabetes as a cardiovascular disease risk equivalent. Curr. Cardiol. Rep. 15, 331 (2013).

  21. 21.

    , , , & Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. Arch. Intern. Med. 171, 404–410 (2011).

  22. 22.

    , , , & Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects. Diabetes Care 31, 714–719 (2008).

  23. 23.

    et al. Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes Care 27, 2898–2904 (2004).

  24. 24.

    , & Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. Nat. Rev. Endocrinol. 9, 479–493 (2013).

  25. 25.

    , , , & Early signs of atherosclerosis in diabetic children on intensive insulin treatment: a population-based study. Diabetes Care 33, 2043–2048 (2010).

  26. 26.

    & Cardiovascular disease risk in young people with type 1 diabetes. J. Cardiovasc. Trans. Res. 5, 446–462 (2012).

  27. 27.

    et al. Longitudinal lipid screening and use of lipid-lowering medications in pediatric type 1 diabetes. J. Pediatr. 150, 146–150 (2007).

  28. 28.

    Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. Diabetes 41 (Suppl. 2), 12–17 (1992).

  29. 29.

    et al. Prevalence and management of hypertension in type 1 diabetes mellitus in Europe: the EURODIAB IDDM Complications Study. Diabet. Med. 16, 41–48 (1999).

  30. 30.

    , , , & Cigarette smoking among adolescents with type 1 diabetes: strategies for behavioral prevention and intervention. J. Diabetes Complications 26, 148–153 (2012).

  31. 31.

    et al. Sex differences in cardiovascular disease risk in adolescents with type 1 diabetes. Gend. Med. 9, 251–258 (2012).

  32. 32.

    et al. Estimated insulin sensitivity and cardiovascular disease risk factors in adolescents with and without type 1 diabetes. J. Pediatr. 162, 297–301 (2013).

  33. 33.

    , , & DCCT/EDIC Research Group. The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) study. Circulation 127, 180–187 (2013).

  34. 34.

    et al. Cardiovascular disease risk factors in youth with type 1 and type 2 diabetes: implications of a factor analysis of clustering. Metab. Syndr. Relat. Disord. 7, 89–95 (2009).

  35. 35.

    , et al. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 46, 1354–1359 (1997).

  36. 36.

    & Epidemiology of macrovascular disease in diabetes. Diabetes Rev. 5, 294–315 (1997).

  37. 37.

    et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316, 823–828 (1998).

  38. 38.

    et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 348, 383–393 (2003).

  39. 39.

    , , & Effect of multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 358, 580–591 (2008).

  40. 40.

    et al. Asymptomatic atherosclerosis and insulin resistance. Arterioscler. Thromb. 11, 1068–1076 (1991).

  41. 41.

    , , & Insulin resistance and coronary artery disease. Diabetologia 39, 1345–1350 (1996).

  42. 42.

    Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. J. Intern. Med. 249, 225–235 (2001).

  43. 43.

    Insulin resistance and coronary heart disease. Curr. Opin. Lipidol. 7, 217–226 (1996).

  44. 44.

    , , , & Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-analysis. PLoS ONE 7, e52036 (2012).

  45. 45.

    , , , & Relationship of insulin resistance and related metabolic variables to coronary artery disease: a mathematical analysis. Diabetes Care 32, 361–366 (2009).

  46. 46.

    & Natural course of insulin resistance in type I diabetes. N. Engl. J. Med. 315, 224–230 (1986).

  47. 47.

    et al. Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks? Diabetologia 56, 1462–1470 (2013).

  48. 48.

    , & Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: “double diabetes” in the Diabetes Control and Complications Trial. Diabetes Care 30, 707–712 (2007).

  49. 49.

    et al. Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: the CACTI study. Diabetes 60, 306–314 (2011).

  50. 50.

    et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Foundation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640–1645 (2009).

  51. 51.

    et al. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 28, 2019–2024 (2005).

  52. 52.

    et al. Metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 32, 950–952 (2009).

  53. 53.

    et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353, 2643–2653 (2005).

  54. 54.

    et al. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes 55, 3556–3565 (2006).

  55. 55.

    Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 53, 1270–1287 (2010).

  56. 56.

    et al. Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. Diabetes 58, 1212–1221 (2009).

  57. 57.

    Cardiovascular disease in type 2 diabetes, from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care 33, 442–449 (2010).

  58. 58.

    & Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 14, 575–585 (2011).

  59. 59.

    et al. Large-scale association analysis identified new risk loci for coronary heart disease. Nat. Genet. 45, 25–33 (2013).

  60. 60.

    et al. General and abdominal obesity parameters and their combination in relation to mortality: a systematic review and meta-regression analysis. Eur. J. Clin. Nutr. 67, 573–585 (2013).

  61. 61.

    , , & Insulin sensitivity differs among ethnic groups with a compensatory response in beta-cell function. Diabetes Care 23, 1353–1358 (2000).

  62. 62.

    et al. Visceral adiposity, not abdominal subcutaneous fat area, is associated with an increase in future insulin resistance in Japanese Americans. Diabetes 57, 1269–1275 (2008).

  63. 63.

    , , , & Relationship between generalized and upper body obesity to insulin resistance in Asian Indian men. J. Clin. Endocrinol. Metab. 84, 2329–2335 (1999).

  64. 64.

    , , , & Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations. Ann. NY Acad. Sci. 1281, 51–63 (2013).

  65. 65.

    et al. The role of adiposity in cardiometabolic traits: a Mendelian randomization analysis. PLoS Med. 10, e1001474 (2013).

  66. 66.

    & Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 32 (Suppl. 2), S157–S163 (2009).

  67. 67.

    et al. Adipocyte turnover: relevance to human adipose tissue morphology. Diabetes 59, 105–109 (2010).

  68. 68.

    , , & Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell. Biol. 9, 367–377 (2008).

  69. 69.

    & The origins and drivers of insulin resistance. Cell 152, 673–684 (2013).

  70. 70.

    , , , & Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest. 95, 2409–2415 (1995).

  71. 71.

    , & Mechanisms linking obesity with cardiovascular disease. Nature 444, 875–880 (2006).

  72. 72.

    & Inflammatory links between obesity and metabolic disease. J. Clin. Invest. 121, 2111–2117 (2011).

  73. 73.

    et al. C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Diabetes 59, 916–925 (2010).

  74. 74.

    et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol. Cell 6, 87–97 (2000).

  75. 75.

    , , & Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 28, 1225–1236 (2008).

  76. 76.

    , , & Ectopic lipid storage and insulin resistance: a harmful relationship. J. Int. Med. 274, 25–40 (2013).

  77. 77.

    & Diabetes mellitus and the beta cell: the last ten years. Cell 148, 1160–1171 (2012).

  78. 78.

    et al. Pancreatic fat content and beta-cell function in men with and without type 2 diabetes. Diabetes Care 30, 2916–2921 (2007).

  79. 79.

    et al. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 108, 3097–3101 (2003).

  80. 80.

    & Diabetes and hypertension: the bad companions. Lancet 380, 601–610 (2012).

  81. 81.

    , , & Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J. Clin. Invest. 85, 1844–1852 (1990).

  82. 82.

    , , , & Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J. Clin. Invest. 94, 1172–1179 (1994).

  83. 83.

    et al. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J. Clin. Invest. 97, 2601–2610 (1996).

  84. 84.

    et al. Macrophage insulin receptor deficiency increases ER stress-induced apoptosis and necrotic core formation in advanced atherosclerotic lesions. Cell Metab. 3, 257–266 (2006).

  85. 85.

    et al. Myeloid lineage cell-restricted insulin resistance protects apolipoprotein E-deficient mice against atherosclerosis. Cell Metab. 3, 247–256 (2006).

  86. 86.

    et al. Increased endoplasmic reticulum stress in atherosclerotic plaques associated with acute coronary syndrome. Circulation 116, 1226–1233 (2007).

  87. 87.

    & Macrophages in the pathogenesis of atherosclerosis. Cell 145, 341–355 (2011).

  88. 88.

    et al. Differences in atherosclerosis plaque burden and morphology between type 1 and 2 diabetes as assessed by multislice computed tomography. Diabetes Care 32, 1507–1512 (2009).

  89. 89.

    , , & Type 1 diabetes and coronary heart artery disease. Diabetes Care 29, 2528–2538 (2006).

  90. 90.

    Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 48, 937–942 (1999).

  91. 91.

    et al. Nonfasting glucose, ischemic heart disease, and myocardial infarction. J. Am. Coll. Cardiol. 59, 2356–2365 (2012).

  92. 92.

    [No authors listed] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 837–853 (1998).

  93. 93.

    , , , & 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577–1589 (2008).

  94. 94.

    Action to Control Cardiovascular Risk in Diabetes Study Group et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545–2559 (2008).

  95. 95.

    ADVANCE Collaborative Group et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560–2572 (2008).

  96. 96.

    et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 360, 129–139 (2009).

  97. 97.

    , & Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 371, 1800–1809 (2008).

  98. 98.

    , , & Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113, 1888–1904 (2006).

  99. 99.

    et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C–dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49, 1939–1945 (2000).

  100. 100.

    , & Vascular system: role of nitric oxide in cardiovascular diseases. J. Clin. Hypertens. (Greenwich) 10, 304–310 (2008).

  101. 101.

    et al. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J. Clin. Invest. 116, 1071–1080 (2006).

  102. 102.

    et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc. Natl Acad. Sci. 97, 12222–12226 (2000).

  103. 103.

    The pathobiology of diabetes complications: a unifying mechanism. Diabetes 54, 1615–1625 (2005).

  104. 104.

    & Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab. 17, 20–33 (2013).

  105. 105.

    et al. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene gene-activating epigenetic marks that coexist on the lyseine tail. Diabetes 58, 1229–1236 (2009).

  106. 106.

    & Oxidative stress and diabetic complications. Circ. Res. 107, 1058–1070 (2010).

  107. 107.

    , & The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ. Res. 106, 842–853 (2010).

  108. 108.

    & The vascular smooth muscle cell: a therapeutic target in type 2 diabetes? Clin. Sci. (Lond) 125, 167–182 (2013).

  109. 109.

    , , & Diabetes duration is associated with increased thin-cap fibroatheroma detected by intravascular ultrasound with virtual histology. Circ. Cardiovasc. Interv. 2, 543–548 (2009).

  110. 110.

    et al. Diabetes adversely affects macrophages during atherosclerotic plaque regression in mice. Diabetes 60, 1759–1769 (2011).

  111. 111.

    , , , & Plasminogen activator inhibitor-1 activity in type 2 diabetes: a different relationship with coronary heart disease and diabetic retinopathy. Arterioscler. Thromb. Vasc. Biol. 28, 786–791 (2008).

  112. 112.

    et al. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes 55, 1807–1812 (2006).

  113. 113.

    , , & Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 49, 1071–1080 (2006).

  114. 114.

    et al. Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care 31, 2006–2012 (2008).

  115. 115.

    et al. Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. Diabetes 60, 582–589 (2011).

  116. 116.

    et al. Endothelial dysfunction and low-grade inflammation explain much of the excess of cardiovascular mortality in individuals with type 2 diabetes: the Hoorn Study. Arterioscl. Thromb. Vasc. Biol. 26, 1086–1093 (2006).

  117. 117.

    , , , & High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study. Diabetes Care 29, 329–333 (2006).

  118. 118.

    et al. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study. Diabetologia 50, 1409–1417 (2007).

  119. 119.

    Heart in diabetes: a microvascular disease. Diabetes Care 34 (Suppl. 2), S145–S149 (2011).

  120. 120.

    , , , & Retinopathy predicts cardiovascular mortality in type 2 diabetic men and women. Diabetes Care 30, 292–299 (2007).

  121. 121.

    et al. Diabetic retinopathy is associated with an increased incidence of cardiovascular events in Type 2 diabetic patients. Diabet. Med. 25, 45–50 (2008).

Download references

Author information

Affiliations

  1. Institute of Clinical Science, Internal Medicine, University of Eastern Finland and Kuopio University Hospital, Yliopistonranta 1E, 70210 Kuopio, Finland.

    • Markku Laakso
    •  & Johanna Kuusisto

Authors

  1. Search for Markku Laakso in:

  2. Search for Johanna Kuusisto in:

Contributions

Both authors contributed equally to all aspects of the manuscript.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Markku Laakso.